Maternova has entered a multinational distribution agreement with MedMira to market rapid diagnostics for human immunodeficiency virus (HIV), syphilis and hepatitis.

As part of the agreement, Maternova will exclusively supply MedMira’s Reveal, Multiplo and Miriad brands across Latin America.

Developed to reduce HIV, hepatitis and syphilis as well as other infectious and sexually transmitted diseases, the company will also have non-exclusive rights for the products in the US.

Maternova founder and strategy chief Meg Wirth said: “Sexually transmitted infections are a growing threat to maternal and infant health.

“MedMira’s Rapid Vertical Flow platform provides tests with immediate results that are highly sensitive and specific, all of the qualities needed by clinicians.”

Designed to reduce mother-to-child transmission (MTCT) of syphilis and HIV, the Multiplo TP/HIV rapid test is claimed to deliver 100% sensitivity in detecting co-infections.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to data from recent studies carried out by the Centers for Disease Control and Prevention (CDC), the Reveal G4 HIV rapid test is also claimed to offer the highest sensitivity and specificity.

These products are exclusively manufactured at a facility in Canada that is US Food and Drug Administration (FDA) and Medical Device Single Audit Program (MDSAP) certified.

MedMira CEO Hermes Chan said: “MedMira has developed a number of highly valuable and essential rapid tests to provide immediate quality answers in any setting.

“Our core focus is the development and manufacturing of our technologies and products, and we are delighted to partner with Maternova to access new markets and new customers.”